Pembrolizumab (pembro) in Mismatch Repair-Deficient (dMMR) Advanced Colorectal Cancer (CRC): KEYNOTE-164 Japan Subgroup
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz339.012
Abstract: Abstract Background Pembro is approved for microsatellite instability-high (MSI-H)/dMMR CRC that has progressed on fluoropyrimidine+oxaliplatin+irinotecan (Fp+Ox+Ir), based in part on data from the ongoing phase 2 KEYNOTE-164 study (NCT02460198). The outcomes of the Japan (Jpn)… read more here.
Keywords: cohorts ajpn; subgroup; dmmr; keynote 164 ... See more keywords